Search clinical trials for: INCB001158

Total 5 results

Incyte Biosciences Japan GK

Completed

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Japan
Incyte Corporation

Terminated

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States, Spain, Germany
Incyte Corporation

Completed

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Ovarian Cancer | Endometrial Cancer | Solid Tumors | Biliary Tract Cancer (BTC) | Colorectal Cancer (CRC) | Gastroesophageal Cancer (GC)

United Kingdom, United States, Belgium
Incyte Corporation

Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Head and Neck Cancer | Gastric Cancer | Lung Cancer | Metastatic Cancer | Mesothelioma | Bladder Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer)

Italy, Spain, United States, Netherlands
Incyte Corporation

Terminated

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Solid Tumors

United States

3

Subscribe